Loading…

See where your brand stands in AI answers

Free. About a minute. No sign-up.

Know where you stand. Find your next opportunity.

Products

Brands
Markets
Topics
Work with us
Pricing

Resources

Research
Methodology
Blog
MCP
For AI

Compare

Parse vs Profound
Parse vs Peec AI
Parse vs AthenaHQ
Parse vs Scrunch
Parse vs Otterly.AI
All comparisons

Company

About
Dimitry Apollonsky
Contact us
Corrections

Pricing

What AI says about Regeneron Ventures | Parse

Brands

Brands

Regeneron Ventures

What AI says about Regeneron Ventures

Track Regeneron Ventures free

AI named Regeneron Ventures in July 2026.

Regeneron Ventures in AI’s own words

Question: What are the latest affordable advancements in biopharma for treating rare diseases?

Google AI ModeJul 20, 2026

Small biotech firms are increasingly partnering with larger pharmaceutical companies (e.g., Regeneron Ventures, Deerfield Management ) to share the costs of clinical development.

Ask Google AI Mode yourself (opens in a new tab)

Track Regeneron Ventures: see where AI mentions it and what to do next.

Track Regeneron Ventures

Competitors

AI named Regeneron Ventures alongside CASGEVY, Deerfield Management, and PaVe-GT

See where AI mentions Regeneron Ventures

Track Regeneron Ventures

See where AI mentions Regeneron Ventures

Track Regeneron Ventures

CASGEVY
Deerfield Management
PaVe-GT

Sources AI cites

AI leaned on pmc.ncbi.nlm.nih.gov, pharmtech.com, and biopharminternational.com in the answers that named Regeneron Ventures.

pmc.ncbi.nlm.nih.gov (opens in a new tab)21%
pharmtech.com (opens in a new tab)14%
biopharminternational.com (opens in a new tab)7%
bioprocessintl.com (opens in a new tab)7%
ddw-online.com (opens in a new tab)7%

Questions and answers

What are the latest affordable advancements in biopharma for treating rare diseases?
Excerpts where Regeneron Ventures appeared in the AI's answer
Google AI ModeJul 20, 2026, Google AI Mode
Small biotech firms are increasingly partnering with larger pharmaceutical companies (e.g., Regeneron Ventures, Deerfield Management ) to share the costs of clinical development.